Mycoplasma

M Bio Technology

Mycoplasma

Glycolipid

Antigen

Vaccine

Technology Readiness Level : 

5

/ 9

Business stage : 

Series B stage / global alliance

Filed Patents : 

2

M Biotech has key patents for the structure of glycolipid on mycoplasma membrane surfaces as well as its synthesis methodology. These technologies could be applied both for high sensitive diagnoses and vaccine development with applying the glycolipid-antigen to produce its antibody. M Biotech encourages global business expansion with identifying the business and technical partners.

Regenerative medicine

Cellusion

Cell therapy

Ophthalmology

Allogeneic

iPSC

Technology Readiness Level : 

5

/ 9

Business stage : 

Series A stage
Series B stage

Filed Patents : 

4

Cellusion has own IP and technologies to develop and obtain iPS-derived corneal endothelial cells suitable for corneal transplantation to be able to treat thousands of patients from a single batch.

Regenerative medicine

MiCAN

Human iPSC

Myeloid linage cells

Immature dendritic cells

COVID-19

Technology Readiness Level : 

7

/ 9

Business stage : 

Spinout / Seed fund stage

Filed Patents : 

Not disclosed

MiCAN develops iPS-derived myeloid (immature dendritic cells) to be applied for virus research (including dengue and COVID-19) as well as for drug safety applications.

Surgical data

Surg storage

Endoscopic Surgery

Big data

AI assisted

Robotics

Technology Readiness Level : 

7

/ 9

Business stage : 

Spinout / Seed fund stage

Filed Patents : 

None

Surge storage can now provide surgical videos and surgical-related data for commercial uses such as for the improvement of the quality of the medical devices. Spinout from National Cancer Hospital in Japan.

VR

FOVE

Eye Tracking

Virtual Reality

Glaucoma

Dementia

Technology Readiness Level : 

9

/ 9

Business stage : 

Basic research to POC, Series A

Filed Patents : 

>5

FOVE has unique eye tracking VR system and technologies, and now looking for healthcare application partners such as dementia (cognitive) research fields, e.g. self-check device development.

Regenerative medicine

PuREC

MSC

stem cell therapy

hypophosphatasia

disc herination

Technology Readiness Level : 

6

/ 9

Business stage : 

Series A stage

Filed Patents : 

4

PuREC is a Shimane University spinout company having patented technologies to produce extremely purified MSC, or mesenchymal stem cells. PuREC's REC is coming from Rapidly Expanding Cells enabling to obtain 10^12 ordered pure cells within 12 weeks without requiring complicated methodologies including gene-modification.